» Articles » PMID: 30628586

Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland

Overview
Journal Med Sci Monit
Date 2019 Jan 11
PMID 30628586
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND The most common etiological agents of infections in onco-hematological patients are Gram-negative rods resistant to many antimicrobials, including carbapenems. Recently, ceftolozane combined with tazobactam became a novel therapeutic option. The aim of the present study was to analyze the susceptibility to ceftolozane/tazobactam of the clinical strains of these bacteria. MATERIAL AND METHODS Material comprised rectal swabs, urine, and bronchoalveolar lavage fluid obtained from onco-hematological patients hospitalized in a clinical hospital (1050 beds) in Poland. Identification of the isolated bacteria was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) using the MALDI Biotyper (Bruker). Ceftolozane/tazobactam susceptibility of the isolates was assessed using antimicrobial gradient strips (E-test, BioMérieux). Antimicrobial susceptibility testing and interpretation of the results was done according to the current recommendations of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). RESULTS In total, 281 rectal swabs and 116 urine samples were tested for the presence of Gram-negative rods producing ESBL, and 531 rectal swabs and 8 bronchoalveolar lavage fluid samples were tested for the presence of Gram-negative rods resistant to carbapenems. In the analyzed period, 69 non-repetitive strains of bacteria were isolated that were in the spectrum of activity of ceftolozane/tazobactam. Among 44 clinical strains of ESBL(+) Enterobacteriaceae rods, 76% were susceptible to ceftolozane/tazobactam. All 9 strains of non-carbapenemase-producing P. aeruginosa resistant or with decreased susceptibility to carbapenems were susceptible to ceftolozane/tazobactam. CONCLUSIONS Ceftolozane/tazobactam may be an option in the therapy of infections caused by ESBL(+) strains of Enterobacteriaceae as well as non-carbapenemase-producing carbapenem-resistant strains of P. aeruginosa.

Citing Articles

Global evaluation of the antibacterial activity of Ceftolozane/Tazobactam against ESBLs-producing and : a systematic review and meta-analysis.

Khorasani M, Rostami S, Bakhshi A, Sheikhi R Ther Adv Infect Dis. 2023; 10:20499361231212074.

PMID: 38029068 PMC: 10656798. DOI: 10.1177/20499361231212074.


Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant But Not against Isolates.

Sekowska A, Grabowska M, Bogiel T Medicina (Kaunas). 2023; 59(3).

PMID: 36984519 PMC: 10057464. DOI: 10.3390/medicina59030518.


Infections in Cancer Patients.

Paprocka P, Durnas B, Mankowska A, Krol G, Wollny T, Bucki R Pathogens. 2022; 11(6).

PMID: 35745533 PMC: 9230571. DOI: 10.3390/pathogens11060679.


Evaluation of activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against and -the EM200 study.

Belkhair J, Nachat S, Rouhi S, Ouassif H, Abbassi S, Soraa N New Microbes New Infect. 2021; 41:100872.

PMID: 33912351 PMC: 8066805. DOI: 10.1016/j.nmni.2021.100872.


Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Infections.

Vrancianu C, Dobre E, Gheorghe I, Barbu I, Cristian R, Chifiriuc M Microorganisms. 2021; 9(4).

PMID: 33807464 PMC: 8065494. DOI: 10.3390/microorganisms9040730.


References
1.
Moya B, Dotsch A, Juan C, Blazquez J, Zamorano L, Haussler S . Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog. 2009; 5(3):e1000353. PMC: 2654508. DOI: 10.1371/journal.ppat.1000353. View

2.
Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K . In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006; 51(3):826-30. PMC: 1803152. DOI: 10.1128/AAC.00860-06. View

3.
Moya B, Zamorano L, Juan C, Ge Y, Oliver A . Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54(9):3933-7. PMC: 2934984. DOI: 10.1128/AAC.00296-10. View

4.
Hansen D, Schumacher H, Hansen F, Stegger M, Hertz F, Schonning K . Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, β-lactamase distribution, phylogroups, and co-resistance. Scand J Infect Dis. 2012; 44(3):174-81. DOI: 10.3109/00365548.2011.632642. View

5.
Skalweit M . Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections. Drug Des Devel Ther. 2015; 9:2919-25. PMC: 4461093. DOI: 10.2147/DDDT.S61436. View